Boulder, CO, United States of America

Rui Xu

USPTO Granted Patents = 33 

 

 

Average Co-Inventor Count = 9.1

ph-index = 10

Forward Citations = 282(Granted Patents)


Location History:

  • New York, NY (US) (2003)
  • Longmont, CO (US) (2006 - 2016)
  • Boulder, CO (US) (2012 - 2016)
  • Dallas, TX (US) (2017 - 2024)

Company Filing History:


Years Active: 2003-2024

Loading Chart...
Loading Chart...
Loading Chart...
33 patents (USPTO):

Title: Innovations by Rui Xu: Advancing Cancer Treatment

Introduction

Rui Xu, an accomplished inventor based in Boulder, Colorado, has made significant contributions to the field of pharmacology and oncology, holding a remarkable 33 patents to his name. His work primarily focuses on the development of HIF-2α inhibitors, which have shown promising results in treating various cancers.

Latest Patents

Rui Xu's latest patents include groundbreaking discoveries such as "Aryl Ethers and Uses Thereof." This patent discusses HIF-2α inhibitors and outlines methods for making and using these compounds to treat cancer. Research shows that certain compounds demonstrated potent activity in HIF-2α scintillation proximity assays and other evaluations, leading to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

Another significant patent is "Aromatic Compounds and Uses Thereof." This document reveals valuable substituted indane derivatives, which serve as HIF-2α inhibitors. The pharmaceutical compositions outlined in this patent have potential applications in treating proliferative diseases, including renal cell carcinoma and von Hippel-Lindau disease, as well as conditions associated with HIF-2α activity.

Career Highlights

Throughout his career, Rui Xu has worked with prominent companies in the biotech and pharmaceutical industry, including Array Biopharma Inc. and Genentech, Inc. His contributions to these organizations have enhanced their drug development capabilities and broadened their therapeutic offerings.

Collaborations

Rui has had the pleasure of collaborating with distinguished professionals such as James F. Blake and Eli M. Wallace. These partnerships have fostered innovation and advancement in their shared research interests, particularly in the area of cancer treatment.

Conclusion

Rui Xu stands out as a leading figure in cancer research and drug development, with a solid portfolio of patents that reflects his dedication and ingenuity. His innovative work in HIF-2α inhibitors is paving the way for new treatments for patients battling various forms of cancer, highlighting the significant impact of his research on the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…